CUE BIOPHARMA, INC.

Analyst Reco. Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.24 ^USD	-11.43%		-8.15%	-53.03%

06-07	Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee	CI
05-09	Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Starts Cue Biopharma With Buy Rating	03-13	MT
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating	11-06	MT
Stifel Adjusts Cue Biopharma's Price Target to $8 From $9, Keeps Buy Rating	22/03/23	MT
Piper Sandler Starts Cue Biopharma at Overweight With $7 Price Target	21/11/22	MT
Oppenheimer Adjusts Cue Biopharma's Price Target to $10 From $26, Maintains Outperform Rating	24/08/22	MT
JMP Securities Adjusts Cue Biopharma's Price Target to $15 From $30, Maintains Market Outperform Rating	23/03/22	MT
Oppenheimer Adjusts Cue Biopharma's Price Target to $26 From $32, Maintains Outperform Rating	21/03/22	MT
Craig-Hallum Adjusts Cue Biopharma's Price Target to $26 From $28, Keeps Buy Rating	18/03/22	MT
HC Wainwright Starts Cue Biopharma at Buy with $20 Price Target	13/01/22	MT
Craig-Hallum Starts Cue Biopharma at Buy with $28 Price Target	03/01/22	MT
CUE BIOPHARMA : Berenberg Starts Cue Biopharma at Buy With $30 Price Target	24/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer